Rebiotix Seeking to Pioneer Microbiota Restoration
By Marie Powers
Friday, September 27, 2013
Rebiotix Inc. has sprinted from concept to clinical application in less than two years in pursuit of treatment for gastrointestinal diseases, such as recurring Clostridium difficile infection (CDI), using the human microbiome – the collective genomes of the human microbiota. In July, the FDA approved the Roseville, Minn.-based company’s investigational new drug application for lead candidate RBX2660 (microbiota suspension).
Outside of the US
Part of Thomson Reuters
Note: our contact information has changed
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
© 2017 Thomson Reuters. Reproduction, reposting content is strictly prohibited.